Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lupin Limited sales and profits grow in second quarter

Lupin Limited sales and profits grow in second quarter

4th November 2010

Lupin Limited has published its financial report for the second quarter of its 2010-11 business year, during which it experienced top-line year-on-year growth of 26 percent.

The generic drugs manufacturer accrued a net sales total of 14 billion rupees (195.8 million pounds) for the quarter, while net profits for the period saw a 34 percent increase to 2.4 billion rupees.

This performance was led by a 40 percent growth in formulation sales in advanced markets – including Europe, the US and Japan – while double-digit increases were also noted in emerging regions.

Dr Kamal Sharma, managing director at Lupin Limited, noted that the company has now experienced sustained growth for the last 18 quarters.

He said this is "not only a reflection of the strong business philosophy guiding us, but also a vindication of our robust vertically-integrated business model".

Earlier this week, the company received clearance from healthcare regulators in the US to launch its new Suprax range of chewable tablets.ADNFCR-8000103-ID-800217769-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.